Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Interventions

Study Locations

Facility	City	State	Country
PersonGen Biomedicine (Suzhou) Co., Ltd.	Suzhou	Jiangsu	China

Official Trial Information

View on ClinicalTrials.gov